Literature DB >> 3193028

Immunomodulation by pulmonary surfactant.

A Catanzaro1, P Richman, S Batcher, M Hallman.   

Abstract

Canine pulmonary surfactant is recognized to modulate both T and B cell response in vitro. Because both responses involve cell proliferation, it has been suggested that surfactant interferes with the proliferation of lymphocytes. We herein report studies using human surfactant collected from amniotic fluid (HAFS). HAFS inhibited the proliferative response of human lymphocytes to antigen (PPD) and to allogeneic lymphocytes. Inhibition was linear within the dose range examined. Inhibition of the response to phytohemagglutinin was only evident when suboptimal doses of phytohemagglutinin were used. The effect of HAFS on the lysis of K562 human myeloid target cells by natural killer (NK) cells was also studied. Lysis in this system does not require proliferation. HAFS inhibited NK cell-induced lysis by 70% (250 micrograms HAFS per milliliter) to 95% (500 micrograms HAFS per milliliter). Inhibition was evident whether the cells were incubated with HAFS for 4 hours or for 18 hours. The NK suppressor activity was contained in the lipid fraction of HAFS, whereas the protein fraction revealed little activity. The washout experiments demonstrated that the action of HAFS was on NK cells and not on target cells. The immunomodulatory properties of surfactant affect NK cell activity and the proliferative response. Surfactant may protect the lungs from inappropriate immune reactions. Abnormalities of the lipid fraction of surfactant should be considered in studies of the mechanism of pulmonary diseases characterized by local pulmonary immune responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3193028

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  Surfactant prevents quartz induced down-regulation of complement receptor 1 in human granulocytes.

Authors:  G Zetterberg; J Lundahl; T Curstedt; A Eklund
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

2.  Aberrant lung remodeling in a mouse model of surfactant dysregulation induced by modulation of the Abca3 gene.

Authors:  Michael F Beers; Lars Knudsen; Yaniv Tomer; Julian Maronn; Ming Zhao; Matthias Ochs; Surafel Mulugeta
Journal:  Ann Anat       Date:  2016-12-26       Impact factor: 2.698

3.  Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung.

Authors:  Y Cormier; E Israël-Assayag; M Desmeules; O Lesur
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

4.  Immunogenicity of surfactant. I. Human alveolar surfactant.

Authors:  D S Strayer; M Hallman; T A Merritt
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

5.  Early effects of short-time cigarette smoking on the human lung: a study of bronchoalveolar lavage fluids.

Authors:  N M Mancini; M C Béné; H Gérard; F Chabot; G Faure; J M Polu; O Lesur
Journal:  Lung       Date:  1993       Impact factor: 2.584

Review 6.  Cellular events in alveolitis and the evolution of pulmonary fibrosis.

Authors:  A Burkhardt; H Cottier
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

7.  Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes.

Authors:  Markus Fehrholz; Kirsten Glaser; Silvia Seidenspinner; Barbara Ottensmeier; Tore Curstedt; Christian P Speer; Steffen Kunzmann
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

Review 8.  The surfactant system of the adult lung: physiology and clinical perspectives.

Authors:  H Hamm; H Fabel; W Bartsch
Journal:  Clin Investig       Date:  1992-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.